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Patient-reported outcomes following treatment
with the human GLP-1 analogue liraglutide or glimepiride
in monotherapy: results from a randomized controlled
trial in patients with type 2 diabetes
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Aim: As weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological
well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors.
Methods: Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week,
double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Results: Mean (SE) decreases in glycated haemoglobin levels were greater with liraglutide 1.2 mg [−0.84 (0.08)%] and 1.8 mg [−1.14
(0.08)%] than glimepiride [−0.51 (0.08)%; p = 0.0014 and p < 0.0001, respectively]. Patients gained weight on glimepiride [mean (SE), 1.12
(0.27) kg] but lost weight on liraglutide [1.2 mg: −2.05 (0.28) kg; 1.8 mg: −2.45 (0.28) kg; both p < 0.0001]. Patient weight assessment
was more favourable with liraglutide 1.8 mg [mean (SE) score: 40.0 (2.0)] than glimepiride [48.7 (2.0); p = 0.002], and liraglutide 1.8 mg
patients were 52% less likely to feel overweight [odds ratio (OR) 0.48; 95% conﬁdence interval (CI): 0.331–0.696]. Mean (SE) weight concerns
were less with liraglutide [1.2 mg: 30.0 (1.2); 1.8 mg: 32.8 (1.2)] than glimepiride [38.8 (1.2); p < 0.0001 and p < 0.001, respectively], with
liraglutide groups 45% less likely to report weight concern (OR 0.55, 95% CI: 0.41–0.73). Mean (SE) mental and emotional health and general
perceived health improved more with liraglutide 1.8 mg [476.1 (2.8) and 444.2 (3.2), respectively] than glimepiride [466.3 (2.8) and 434.5
(3.2), respectively; p = 0.012 and p = 0.033, respectively].
Conclusions: Improved glycaemic control and decreased weight with liraglutide 1.8 mg vs. glimepiride can improve psychological and
emotional well-being and health perceptions by reducing anxiety and worry associated with weight gain.
Keywords: GLP-1, new treatments, quality of life, type 2 diabetes, weight issues
Date submitted 14 October 2009; date of ﬁrst decision 15 December 2009; date of ﬁnal acceptance 17 December 2009
Introduction
Although insulin therapy has been shown to improve the
health outcomes of patients with type 2 diabetes, its initia-
tion and intensiﬁcation are commonly postponed because of
concerns over the burden of daily injections, regimen com-
plexity and the often attendant hypoglycaemia and weight
gain [1,2]. Even though oral antihyperglycaemic agents are
often favoured as initial therapies because their regimens may
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E-mail: bbode001@aol.com
∗See Appendix 1 for list of participating investigators in the LEAD-3 Study Group.
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be less burdensome, they are also not without side effects,
including hypoglycaemia and/or weight gain (sulphonylureas,
meglitinides, thiazolidinediones), and gastrointestinal symp-
toms (biguanides, alpha-glucosidase inhibitors [3,4]). The
impact of such side effects on patient-centred outcomes, such
as body image, weight and health perceptions, psychological
well-being and cognitive impairment, must be factored into
treatment decisions. The importance of weight gain as a side
effect of treatment has been given a lower priority compared
withhypoglycaemiaandgastrointestinalproblems.However,it
isaparticularconcerninthispatientpopulationandisincreas-
ingly reﬂected in treatment algorithms [3]. The most recent
consensus statement for glycaemic control in type 2 diabetes
issued by the American Association of Clinical Endocrinolo-
gists (AACE) and American College of Endocrinology (ACE)
pointed out that the beneﬁts of GLP-1 agonists, wherebyDIABETES, OBESITY AND METABOLISM original article
approximately 30% of patients experience considerable weight
loss, might in fact supersede transitory gastrointestinal side
effectsandtheinconvenienceoftwice-dailyinjections [5].Over
80% of patients with type 2 diabetes are already either over-
weightorobese [6],andthusweightgainisbothphysicallyand
psychologicallyundesirable.Itmayalsobe abarriertothecon-
tinuation or intensiﬁcation of many antidiabetic therapies [7].
Tailoring diabetes treatments to address patients’ individual
pathophysiology, while balancing the risk of hypoglycaemia
and weight gain, is therefore a signiﬁcant challenge.
Evidence has shown that the health-related quality of life
(HRQoL) of people with type 2 diabetes is compromised com-
pared with general population norms, especially for physical
functioning and well-being [8]. A number of factors have
been implicated, including poor glycaemic control [9], obe-
sity [10,11], treatment side effects (e.g. hypoglycaemia [12])
and especially the presence of diabetes complications [8,13].
The complexity of diabetes regimens might also impact on
HRQoL [8,14], resulting in reduced adherence to therapy [15]
and, as a consequence, reduced therapeutic effectiveness.
Liraglutide is a once-daily analogue of human glucagon-
like peptide-1 (GLP-1), and the molecule shares 97% of
the amino acid sequence of native GLP-1. The efﬁcacy and
safety of liraglutide treatment has been compared with those
of standard treatments across the continuum of care in
type 2 diabetes in a comprehensive phase 3a trial programme
[Liraglutide Effect and Action in Diabetes (LEAD) trial
programme [16–21]]. The results of the LEAD-3 liraglutide
monotherapy trial have previously been reported [18]. In this
study of patients previously treated with diet and exercise or
with half-maximal doses or less of oral antidiabetic (OAD)
monotherapy, liraglutide monotherapy was associated with
greater reductions in glycated haemoglobin (HbA1C) levels,
weight, systolic blood pressure and with less hypoglycaemia
than glimepiride monotherapy. Here, we report the impact
of liraglutide and glimepiride monotherapies on patients’
self-reported perceptions of body image, weight and weight
concern, psychological well-being and distress, cognitive
functioning and health using data from the LEAD-3 trial.
Methods
Overview of the LEAD-3 Trial
Methodological details and clinical results for the LEAD-3
trial have been published elsewhere [18] (Clinical trial
no.: NCT00294723, registered at ClinicalTrials.gov). In this
randomized, double-blind, double-dummy, parallel-group
study, participants were recruited from Mexico (12 sites) and
the United States (126 sites), starting on 7 February 2006, with
the last patient visit on 7 November 2007. In the main clinical
trial,patientswerestratiﬁedbybaselinediabetestreatment(diet
and exercise vs. OAD monotherapy) and randomly allocated
to once-daily treatment with liraglutide 1.2 mg (n = 251) or
1.8 mg (n = 247),or glimepiride 8 mg (n = 248)for 52 weeks.
The primary clinical endpoint was the change in HbA1C
levels from baseline to 52 weeks. Secondary clinical endpoints
includedchangesinfastingplasmaglucose(FPG),8-pointself-
monitored plasma glucose proﬁles, body weight, incidence of
hypoglycaemia and assessment of patient-reported outcomes.
Local institutional review boards approved the protocol and
patientsprovidedwritteninformedconsentbeforetrial-related
activitieswereinitiated.Thestudywasconductedinaccordance
with the Declaration of Helsinki.
Patient-reported Outcomes
The patient-reported outcome assessments were performed as
part of the LEAD-3 trial, with separate methodologies and
statistical analysis plans. The type 2 diabetes modules were
developedbytheRandCorporationandPhaseV Technologies,
Inc. [22,23] and have been previously validated against a
large reference database (4571 subjects in 13 clinical studies
conducted in 1987–2000). Furthermore, the questionnaires
have been used in 15 clinical trials of type 2 diabetes [9,24,25].
ThebatteryofscalesincludedintheLEAD-3trialcomprised
77 self-administered questions. A description of the weight
perception, body image and quality of life scales and items
is given in Appendix 2. The questionnaire was completed at
screening (week −3) for some patients, and for all patients
at baseline (week 0), during (week 28) and at the end of
treatment(week 52),andatstudyexitforpatientswithdrawing
prematurely.Allquestionnairesandevaluationswereprocessed
and analysed independently by a centralized health outcomes
laboratory (Phase V Technologies, Inc., Wellesley Hills, MA)
using the Phase V® Outcomes Information System.
Statistical Analyses
The changes in six patient-reported outcome measures
during 52 weeks of liraglutide or glimepiride treatment were
compared. Analyses were performed on patients allocated
to treatment, who received at least one dose of treatment
and completed a baseline questionnaire. The screening
questionnaire, if available, was used in place of a missed
baseline assessment. Baseline and post-baseline values were
carried forward to replace missing post-baseline values. To
test the validity of these imputations, conﬁrmatory analyses
were conducted in two subgroups: (i) omitting patients with
only baseline values and (ii) only patients completing both
baseline and week 52 assessments. The effect of liraglutide
and glimepiride treatments on the patient-reported outcomes
was examined using linear mixed models. All treatment
effects were adjusted for baseline score and age; country
and sex were also included if statistically signiﬁcant in the
model. Post-randomization measures at weeks 28 and 52 were
tested for between-week and treatment effects. Baseline to
week 28 and baseline to week 52 changes were not evaluated
separately as the week-by-treatment interaction effects were
not statistically signiﬁcant. Statistically signiﬁcant between-
week effects were retained in the models. Ordinal and logistic
regression was used to model treatment differences between
theproportionsofindividualswithinthevariousweight-image
and weight-concern response categories. Associations among
patient-reported outcomes changes and glycaemic control
were evaluated by correlation and regression. To examine the
multivariaterelationshipsandpotentialcausalpathwayswithin
and between the multiple measures of weight perception and
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concern and quality of life components, structural equation
modelling with latent variables was undertaken [26].
Results
Patient Disposition and Baseline Characteristics
Of the 746 patients enrolled, 14 opted not to participate in
the patient-reported outcomes assessments. All 732 remaining
patients completed a baseline assessment (liraglutide 1.2 mg,
n = 245; liraglutide 1.8 mg, n = 242; glimepiride, n = 245)
and 87.0% (637/732) of these also had at least one post-
baselineassessment.Baselinedemographiccharacteristicswere
similar across treatment groups (Table 1). The group was
well educated, which was reﬂected in family income, and few
patients reported disability or handicap. From the weight
assessment scale, a total of 79.4% of patients considered
themselves to be overweight [somewhat overweight: 47.1%
(344/730); very overweight: 32.3% (236/730)] and, from the
weight concern scale, 71.8% were concerned or worried
about their weight [a little concerned: 24.0% (166/692);
somewhat worried: 23.3% (161/692); very worried: 18.1%
(125/692);extremelyworried:6.4%(44/692)].Clinicalbaseline
characteristics for this study have been detailed earlier [18]:
mean (SD) disease duration, 6.0 (5.5) years; weight, 92.6 kg
(19.6); body mass index (BMI), 33.1 (5.8); HbA1C level,
8.2% (1.1%); 64% of patients had previously been treated
with OAD monotherapy and the remaining patients with diet
and exercise only. Although this clinical dataset included the
14 patients who did not participate in the patient-reported
outcome assessments reported here, the non-participants were
statistically comparable to the participants.
Clinical Endpoints
The results of the clinical endpoints from the LEAD-3 study
are detailed by Garber and colleagues [18] and in Table 2. In
summary, improvements in glycaemic control were greater
in the liraglutide groups than the glimepiride group and,
in pairwise comparisons, greater with the higher dose than
the lower liraglutide dose. Reductions in HbA1C and FPG
levels were signiﬁcantly greater for liraglutide 1.2 mg and
1.8 mg vs. glimepiride (HbA1C: p = 0.0014 and p < 0.0001,
respectively; FPG: p = 0.027 and p < 0.0001, respectively),
and for liraglutide 1.2 mg vs. liraglutide 1.8 mg (HbA1C:
p = 0.0046; FPG: p = 0.0223). Postprandial plasma glucose
values (calculated from the 8-point self-monitored plasma
glucose proﬁles) decreased in all treatment groups; the
difference was signiﬁcant for liraglutide 1.8 mg vs. glimepiride
(p = 0.0038).Previouslytreatment-na¨ ıvepatientsexperienced
larger mean reductions in HbA1C than patients switched
from an OAD drug and, in each case, those randomized to
liraglutide experienced greater mean reductions than those
receiving glimepiride; HbA1C reductions were sustained for
52 weeks of the study [18]. The liraglutide groups lost weight
whereastheglimepiridegroupgainedweight;thedifferencesin
changeinbodyweightfrombaselineweresigniﬁcantlydifferent
for each liraglutide group vs. the glimepiride group (both
p < 0.0001). No major hypoglycaemic events were reported.
The rate of minor hypoglycaemia was signiﬁcantly lower for
Table 1. Demographic characteristics at baseline.
Liraglutide 1.2 mg OD (n = 245) Liraglutide 1.8 mg OD (n = 242) Glimepiride 8 mg OD (n = 245)
Age in years, mean (SD) 53.8 (10.8) 52.2 (10.8) 53.3 (10.9)
Men/women, number (%) 113 (46)/132 (54) 119 (49)/123 (51) 131 (53)/114 (47)
Ethnic origin, number (%)
White 194 (79) 183 (76) 190 (78)
Black or African American 34 (14) 29 (12) 29 (12)
Asian or Paciﬁc Islander 5 (2) 13 (5) 9 (4)
Other 12 (5) 17 (7) 17 (7)
Ethnicity, number (%)
Hispanic/Latino 80 (33) 85 (35) 92 (38)
Other 165 (67) 157 (65) 153 (62)
Married, number (%) 162 (67) 164 (69) 154 (65)
Education, number (%)
Up to 18 years of age 123 (51) 100 (43) 109 (46)
More than 18 years of age 118 (49) 135 (57) 129 (54)
Occupation, number (%)
Paid employment 149 (63) 153 (68) 163 (70)
Retired 52 (22) 38 (17) 34 (15)
Student 2 (1) 2 (1) 1 (<1)
Other 35 (15) 33 (15) 36 (15)
Family income in US$/year, number (%)
<25 000 95 (40) 81 (35) 80 (35)
26 000–60 000 86 (36) 90 (39) 89 (39)
>60 000 56 (24) 59 (26) 61 (27)
Disability or handicap, number (%) 29 (12.1) 18 (7.7) 19 (8.1)
OD, once daily; SD, standard deviation.
Only patients completing a baseline patient-reported outcomes questionnaire are represented in this table.
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Table 2. Clinical endpoints from the study and some data previously reported by Garber and colleagues [18].
Mean (SE) Mean differences between treatment group (95% CI)
Liraglutide
1.2 mg OD
(n = 251)
Liraglutide
1.8 mg OD
(n = 247)
Glimepiride
8m gO D
(n = 248)
Liraglutide 1.2 mg
vs. liraglutide
1.8 mg
Glimepiride
vs. liraglutide
1.2 mg
Glimepiride
vs. liraglutide
1.8 mg
Weight, kg
Baseline 92.5 (1.21) 92.8 (1.32) 93.4 (1.22)
Week 52 LOCF 90.2 (1.22) 90.5 (1.31) 94.4 (1.23)
Change from baseline −2.05 (0.28) −2.45 (0.28) 1.12 (0.27) −4.06 −3.17 −3.52
(−1.11 to 0.30) (−3.87 to −2.47)† (−4.28 to −2.87)†
HbA1c levels, %
Baseline 8.3 (0.06) 8.3 (0.07) 8.4 (0.08)
Week 52 LOCF 7.5 (0.09) 7.2 (0.08) 7.8 (0.08)
Change from baseline −0.84 (0.08) −1.14 (0.08) −0.51 (0.08) −0.29% −0.33% −0.62%
(−0.50 to −0.09)∗∗ (−0.53 to −0.13)∗∗ (−0.83 to −0.42)†
FPG, mmol/l
Baseline 9.3 (0.17) 9.5 (0.17) 9.5 (0.17)
Week 52 LOCF 8.7 (0.20) 8.3 (0.18) 9.3 (0.19)
Change from baseline −0.84 (0.19) −1.42 (0.19) −0.29 (0.19) −0.58 −0.55 −1.13
(−1.07 to −0.08)∗ (−1.04 to −0.06)∗ (−1.62 to −0.64)†
Postprandial
plasma glucose‡, mmol/l
Baseline 11.3 (0.15) 11.4 (0.16) 11.4 (0.17)
Week 52 LOCF 9.7 (0.20) 9.3 (0.16) 10.0 (0.19)
Change from baseline −1.71 (0.19) −2.08 (0.19) −1.36 (0.18) −0.37 −0.35 −0.72
(−0.85 to 0.11) (−0.83 to 0.14) (−1.20 to −0.23)∗∗
Rate ratio estimate (95% CI)
Rate of minor hypoglycaemia, 0.30 0.25 1.96 0.62 0.16 0.10
events/patient (0.29 to 1.30) (0.08 to 0.32)† (0.05 to 0.20)†
year at week 52
FPG, fasting plasma glucose; CI, conﬁdence interval; HbA1C,glycated haemoglobin; LOCF, last observation carried forward; OD, once daily; SE, standard
error.
∗p < 0.05.
∗∗p < 0.01.
†p < 0.0001.
‡Calculated from the 8-point self-monitored plasma glucose proﬁles.
each liraglutide group than for the glimepiride group (both
p < 0.0001).
Effect of Treatment on Patient-reported Outcomes
As shown in Table 3, the mean scores of all patient-reported
follow-up measures were estimated for the three treatment
groups adjusting for baseline score and age (53.1 years).
Both measures of weight perception (weight assessment
and weight concern) were more favourable for liraglutide
than glimepiride. Baseline-adjusted mean weight assessment
compared with the reference point ‘my weight is just right’
was signiﬁcantly more favourable (i.e. shifted from more
overweight to less overweight) for the liraglutide 1.8 mg group
than the glimepiride group (p = 0.002; Table 3).
Furthermore, weight concern decreased markedly in the
liraglutide groups with mean scores signiﬁcantly less than
for glimepiride (liraglutide 1.2 mg, p < 0.0001; liraglutide
1.8 mg, p < 0.001). Logistic regression estimates indicated
that individuals receiving liraglutide 1.8 mg were 52% less
likely to report feeling either ‘somewhat’ or ‘very overweight’
vs. ‘just right’, ‘somewhat underweight’ or ‘very overweight’
during treatment than those receiving glimepiride [odds ratio
(OR) 0.48, 95% conﬁdence interval (CI): 0.331–0.696]. Also,
patients receiving liraglutide 1.8 mg were 39% less likely to
report, on the weight concern scale, being ‘somewhatworried’,
‘very worried’ or ‘extremely worried’ vs. ‘a little concerned’
or ‘not concerned at all’ about their weight during treatment
thanthosereceivingglimepiride(OR0.608,95%CI:0.44–0.85
by logistic regression). Patients receiving liraglutide 1.2 mg
reported a 50% lower likelihood of weight concern (using the
dichotomous classiﬁcation cited above) than those receiving
glimepiride (OR 0.50, 95% CI: 0.36–0.70). The OR for both
liraglutidedosescomparedforthedichotomousweightconcern
variable was 0.55 (95% CI: 0.41–0.73).
There were no statistically signiﬁcant differences between
liraglutidegroupsandtheglimepiridegroupforthebodyimage
scales (body size evaluation and body appearance distress) or
for any of the cognitive functioning and performance scales
during treatment. Furthermore, the results of analyses were
comparable and consistent when performed omitting baseline
observations carried forward and when only patients with
week 52 data were included.
As shown in Table 3, the HRQoLcompositescore improved
more favourably with liraglutide 1.8 mg than with glimepiride
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Table 3. Effect of treatment on patient-reported outcomes.
Contrasts
Baseline Between- Glimepiride Glimepiride
covariate Mean (SE) during treatment treatment vs. liraglutide vs. liraglutide
score Liraglutide Liraglutide Glimepiride F statistic 1.2 mg p-value§ 1.8 mg p-value§
Patient-reported outcomes scale (n = 732) 1.2 mg OD 1.8 mg OD 8 mg OD p-value (p-value)¶ (p-value)¶
Weight perception scales
Weight assessment− 50.6 47.6 (2.0) 40.0 (2.0)∗∗ 48.7 (2.0) 0.003 0.693 0.002
Weight concern− 37.8 30.0 (1.2)‡ 32.8 (1.2)† 38.8 (1.2) <0.0001 <0.0001 (0.0001) <0.001 (0.019)
Body image scales
Body size evaluation− 32.8 27.9 (0.9) 27.4 (0.9) 29.7 (0.9) 0.189 0.167 0.085
Body appearance distress+ 44.0 45.5 (0.6) 47.0 (0.6) 45.5 (0.6) 0.169 0.963 0.108
HRQoL scales
Composite HRQoL+ 450.4 453.8 (2.6) 462.3 (2.6)∗∗ 451.7 (2.6) 0.009 0.556 0.004
Mental and emotional health+ 464.6 464.4 (2.7) 476.1 (2.8)∗ 466.3 (2.8) 0.005 0.631 0.012
Psychological well-being+ 411.5 409.5 (3.1) 424.2 (3.1)∗∗ 412.5 (3.1) 0.002 0.504 0.008
General positive affect+ 408.7 406.5 (3.2) 422.2 (3.2)∗ 411.7 (3.2) 0.002 0.255 0.022
Life satisfaction+ 422.8 422.1 (3.5) 436.9 (3.6) 428.2 (3.6) 0.013 0.227 0.084
Emotional ties+ 433.1 432.8 (6.6) 442.5 (6.7)∗ 418.6 (6.8) 0.042 0.134 0.012
Psychological distress+ 496.6 497.7 (2.9) 507.3 (2.9)∗ 498.4 (2.9) 0.032 0.854 0.030
Anxiety+ 472.3 473.8 (3.3) 482.7 (3.3) 474.0 (3.3) 0.090 0.960 0.061
Depression+ 531.1 530.8 (3.4) 542.2 (3.4) 535.4 (3.4) 0.057 0.339 0.154
Behavioural and emotional
control+
509.2 506.1 (3.4) 524.2 (3.4)‡ 505.1 (3.4) 0.000 0.842 <0.0001
General perceived health+ 430.3 441.4 (3.2) 444.2 (3.2)∗ 434.5 (3.2) 0.089 0.127 0.033
Vitality+ 394.8 407.7 (4.0) 415.3 (4.0) 401.8 (4.0) 0.058 0.305 0.017
General health status+ 432.6 451.9 (3.7)∗∗ 446.2 (3.7) 437.5 (3.7) 0.022 0.006 0.096
Composite cognitive
functioning and
performance+
4.03 4.03 (0.02) 4.08 (0.02) 4.05 (0.04) 0.202 0.525 0.262
SE, standard error; OD, once daily; HRQoL, health-related quality of life.
+indicates that higher scores are better.
−indicates that lower scores are better.
∗p < 0.05, ∗∗p < 0.01, †p < 0.001, ‡p < 0.0001 vs. glimepiride.
§p-value for treatment differences using linear mixed models and all available visit data adjusted for baseline score and age (53.1 years).
¶p-value for treatment differences using ordinal regression on last observation carried forward adjusted for baseline score, age, and sex. All p-values are
nominal unadjusted for multiple comparisons.
(p = 0.004). These favourable improvements were seen in the
compositescalesofmentalandemotionalhealth,psychological
well-being, psychological distress and general perceived health
(all p < 0.05). The higher scores with liraglutide 1.8 mg for
mental and emotional health reﬂected greater improvement in
both domains of psychological well-being (which included
subscales of general positive affect, life satisfaction and
emotional ties) and psychological distress (which included
subscales of anxiety, depression, behavioural and emotional
control)thanglimepiride.Therewerenosigniﬁcantdifferences
for these scales between liraglutide 1.2 mg and glimepiride.
Therewas,however,asigniﬁcantdifferencebetweenliraglutide
1.2 mg and glimepiride in general health status (p = 0.006);
the difference being in favour of liraglutide 1.2 mg. The more
favourable HRQoL scores for liraglutide 1.8 mg compared
with glimepiride were mediated predominantly by greater
improvements in the subscales of emotional and behavioural
control (p < 0.0001), general positive affect (p = 0.022),
emotionalties(p = 0.012),lifesatisfaction(p = 0.084),vitality
(p = 0.017) and general health status (p = 0.096). Other
subscales contributed more moderately to overall treatment
differences. As with the weight assessment, the results of
analyses were comparable and consistent when performed
omitting baseline observations carried forward and when only
patients with week 52 data were included.
Associations Between Changes in Patient-reported
Outcomes and Glycaemic Control
Correlation analyses using data pooled from all treatment
groupsconﬁrmedthatbaseline-to-endpointreductionsinBMI
were correlated with baseline-to-endpoint improvements in
both weight assessment and weight concern (r = 0.19 and
r = 0.25, respectively; p < 0.0001 in both cases), indicating
thatpatients’reportswerevalidrepresentationsofactualweight
losses. In addition, baseline-to-endpoint reductions in HbA1C
corresponded to improvements in general perceived health
(r =− 0.142, p < 0.0001), cognitive functioning composite
score (r =− 0.11, p = 0.006) and cognitive performance (r =
−0.11, p = 0.004). Correlations of change in HbA1C within
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treatment groups with change in patient-reported measures
were strongest for liraglutide 1.8 mg: general perceived health,
r =− 0.19, p = 0.004; cognitive functioning composite score,
r =− 0.18, p = 0.008; and cognitive performance, r =− 0.19,
p = 0.004.
Two latent variables (weight perceptions and HRQoL) were
constructed from linear combinations of the observed scales
to represent treatment changes using a structural equation
modelﬁttothebaseline-to-endpointchangescores.Themodel
represented a very good ﬁt to the actual data (comparative
ﬁt index, 0.98; root mean square error of approximation,
0.055; PCLOSE, 0.322; Figure 1). The beta weights indicate
the contribution of the speciﬁc scale on the latent variable
with larger weights having greater inﬂuence. As shown here,
the change in the weight perceptions latent variable was
more heavily inﬂuenced by weight concern [standardized
beta weight (β) = 1.00] than weight assessment (β = 0.18),
indicating that the anxiety associated with weight gain was
more inﬂuential than the perceived amount of weight gained
during treatment. The β values for the scales associated
with the HRQoL latent variable were relatively comparable,
indicating similar contributions of each scale on HRQoL. The
Figure 1. Structuralequationmodelusingdatapooledfromalltreatment
groups. The relative contributions of patient-reported outcomes (e.g.
weight concern) to structural components (e.g. weight ﬁnal) are detailed
on the straight arrows. The correlation between structural components
is detailed above the curved arrow for all groups combined; analyses
within treatment groups gave estimates of −0.15, −0.22 and 0.03 for the
liraglutide 1.2 mg, liraglutide 1.8 mg and glimepiride groups, respectively.
GPH, general perceptions of health HRQoL, health-related quality of
life; PD, psychological distress; PH, analogue perceived health; PWB,
psychological well-being; WC, weight component; QC, quality of life
component.
structural equation model indicated a statistically signiﬁcant
association between HRQoL and weight concern (β =− 0.15,
p < 0.001), supporting the link between decreased weight
concernandimprovedHRQoL.Thestructuralequationmodel
forliraglutide1.8 mgindicatedthatadecreaseof1 SDinweight
concern was associated with a 22% SD unit improvement in
the HRQoL latent variable (β =− 0.22, p < 0.001).
Discussion
The clinical assessments in the LEAD-3 trial showed that,
compared withglimepiride, liraglutide monotherapywas asso-
ciated with greater improvements in glycaemic control and a
lowincidenceofhypoglycaemiaover52weeks [18].Moreover,
liraglutide treatment was associated with weight loss rather
than the weight gain seen with glimepiride. These previously
reported ﬁndings provide the clinical context for the data
reported here. In our study, patients’ assessments of and con-
cerns about their weight improved signiﬁcantly more during
treatment withliraglutide than withglimepiride. Furthermore,
these more favourable treatment effects were greatest for the
1.8 mg dose of liraglutide. Taken together, patients in the
liraglutide 1.8 mg and 1.2 mg dose groups were 45% less likely
to report being ‘somewhat’ to ‘extremely concerned’ about
their weight during treatment compared with before treat-
ment. Moreover, those receiving 1.8 mg of liraglutide were
52% less likely to report feeling ‘somewhat’ or ‘very over-
weight’ than those receiving glimepiride. These patient reports
were consistent with the actual weight loss reported during the
study.Theabsenceofsigniﬁcantdifferencesbetweentreatment
groups for the body image scales suggests that the body areas
are not those of speciﬁc concern to this study population.
Compared with glimepiride, 1.8 mg liraglutide treatment
was also associated with statistically signiﬁcantly greater
improvements in two domains of HRQoL: mental and
emotional health, and general perceived health. As reported
previously, some improvement is likely because of greater
glycaemic control, which has been shown to increase vitality
and general health functioning [9]. Although the treatment
effects were in the same direction, the failure of the liraglutide
1.2 mg group to achieve statistical signiﬁcance compared with
glimepiride for the QoL scales could be because of the smaller
decrease in glycaemic control in the 1.2 mg group compared
with the 1.8 mg group.
However, the mental health improvements shown in this
study for behavioural and emotional control, life satisfaction,
emotional ties and general positive affect were most likely
driven by a combination of greater glycaemic control, greater
weight loss and perception of weight loss, and reduced
concern about weight gain—all of which achieved statistical
signiﬁcance in the liraglutide 1.8 mg group. Emotional ties,
for example, reﬂect how much of the time individuals feel
that their love relationships are full and complete. The
strong psychological impact of liraglutide 1.8 mg treatment
was not solely the result of reductions in the symptoms of
hyperglycaemia. The increased concern about weight gain and
weight appearance for those receiving glimepiride translated
into increased psychological distress and reduced well-being.
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Using structural equation modelling, the relationship between
decreases in patients’ perception of their weight and distress
with weight gain and improvements in the overall composite
score of the HRQoL measure was conﬁrmed. Although it is
not possible to determine the direction of this causal pathway,
it is highly likely that the decrease in weight concern fuelled
improvements in HRQoL.
This relationship between patients’ concern about their
weight during diabetes therapy and HRQoL has not previously
been reported for patients with type 2 diabetes. The data
in this study support clinical observations that weight loss
and the absence of weight gain during liraglutide treatment
result in a meaningful improvement in HRQoL, which is
mediated at least in part by reduced concerns and distress
about weight. This is an important ﬁnding, as weight control
is a major issue in the management of type 2 diabetes. The
dose-response effect, whereby the 1.8 mg dose of liraglutide
showed a greater improvement compared with glimepiride
thandidtheliraglutide1.2 mgdosecomparedwithglimepiride,
supports a causal relationship between liraglutide treatment
and improvements in HRQoL.
Over80%ofpatientswithdiabetesareoverweightandmany
present with hypertension, a major risk factor for coronary
arterydisease.Thisisexacerbatedbymanyexistingtreatments,
which improve glycaemic control at the expense of weight
gain [3]. In addition, weight gain (or fear of weight gain) is
a major negative inﬂuence on treatment adherence [15]. In
the development of the AACE/ACE type 2 diabetes treatment
algorithm,sixgoalswereestablishedasprioritiesintheselection
of medications. One of these goals was ‘minimizing risk
and magnitude of weight gain’. In light of this, a treatment
that results in both weight loss and demonstrable changes
in patients’ concern about their weight which can positively
impact QoL represents a major advance in the management
of this disease, potentially facilitating improved adherence and
glycaemic control.
Patients’ concern and distress because of weight gain
differentials during treatment were not simply psychosomatic
manifestations as the data also showed that changes in BMI
were correlated with changes in patients’ perceptions and
distress with weight. The data also conﬁrmed that concerns
and perceptions were signiﬁcantly related to changes in an
overallscorereﬂectingmentalandemotionalhealthandgeneral
perceived health. The improvement in HbA1C levels during
treatment was also found to be related to improvements in
HRQoL. Associations between improved glycaemic control
and aspects of HRQoL have been reported earlier, but they are
not evident in all investigations [8,9,27]. Testa and Simonson
suggested that the relationship between glycaemic control and
HRQoL may sometimes be masked by the adverse effects of
treatment-related hypoglycaemia on HRQoL [9]. As the rate
of hypoglycaemia is very low with liraglutide, this may also be
the reason that a glycaemic control–HRQoL relationship was
detected in the present study.
Collectively,theﬁndingsfromtheLEAD-3trialsuggestthat,
through the complex interplay of clinical and patient-reported
outcome beneﬁts, liraglutide treatment has the potential to
impact positively on patients’ adherence to treatment, which
is critical to the achievement of glycaemic targets. Recent data
from the USA show that approximately 40% of patients with
type 1 or type 2 diabetes have HbA1C levels in excess of the
7% treatment target [28], and thus remain at increased risk
of various health complications. A treatment that results in
improved self-management is likely to bring more of these
patients under better glycaemic control.
Several possible limitations to the study should be
considered. Firstly, post-baseline data were imputed for 95
patients (13.0%). However, the imputation method carried
baseline and last observations forward, acting to reduce
estimates of the treatment effect. As analytic models not using
imputed data gave comparable results to those presented here,
we are conﬁdent that discontinuation after randomization did
not introduce bias. Secondly, although the nature and extent
of the signiﬁcant treatment results support the robustness
of analyses, the pattern of changes during the year-long
study could potentially have been more fully characterized
by including more assessment points. Finally, we have not
assessed the impact of liraglutide on other important patient-
centred health measures, such as treatment satisfaction and
adherence, which would be useful goals of future research.
In summary, the analyses from this large, active-controlled
clinicaltrialofpatientswithtype 2diabetesshowthatliraglutide
1.8 mg treatment by once-daily injection is associated with
signiﬁcantlygreaterimprovementsinself-reportedperceptions
of body weight and measures of HRQoL than oral glimepiride
treatment.Whathasalsobeenshownhere,andfortheﬁrsttime,
is a signiﬁcant association between decreasing concerns about
weight and improvements in key domains of HRQoL. Given
the inﬂuence of patient-centred factors on self-management
behaviours in type 2 diabetes, these collective ﬁndings suggest
liraglutide treatment may be a useful therapy for achieving
glycaemic targets.
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Appendix 2. Quality of life, weight
perceptions and body image scales
Weight Perception Scales
Weightassessment: one-item, ﬁve-choice, bidirectionalLikert
scale reﬂecting the subject’s perception of their weight that
day. Question stem was: ‘Considering your weight today, do
you consider yourself to be.....’; response choices were: (i) very
underweight,(ii) somewhatunderweight,(iii) myweightisjust
right, (iv) somewhat overweight, and (v) very overweight.
Weight concern: one-item, ﬁve-choice, unidirectional Likert
scale assessing the subject’s distress and concern associated
with his or her weight. Question stem was: ‘Thinking about
your weight now and your weight before you started the study
drugs you are now taking, how concerned are you about your
weight now?’; response choices were: (i) extremely worried and
upset,(ii)veryworried,(iii)somewhatworriedandconcerned,
(iv) a little concerned, and (v) not concerned at all.
Body Image Scales
Seven items for each scale (body size evaluation and body
appearance distress) assessing the subject’s perception of the
relative size of seven different body parts [face, breasts, belly,
dorsalfat(buffalohump), legs,arms,buttocks]comparedwith
self-anchored ‘healthy look’. The question stem was ‘Think
about how you would look if you were ‘‘healthy’’. Now consider
your‘‘currentappearance’’.Comparedtoyourhealthylook,please
comment about how your feel regarding the following areas of
your body.’ Sample items for belly size are shown below:
Body Size Evaluation
Body Appearance Distress
Body size evaluationcodes Body appearance distress codes
Compared to my healthy look my current amount or size is
1 = A great deal less/very
muchsmallerorthinner
1 = Extremely upsetting and
distressing
2 = A lot less/much smaller
or thinner
2 = Very upsetting and
distressing
3 = Somewhat less/smaller
or thinner
3 = Quite upsetting and
distressing
4 = A little less/smaller or
thinner
4 = A little upsetting
5 = Aboutright 5 = No feeling either way
6 = A little more or bigger 6 = A little encouraging
7 = Somewhat more or
bigger
7 = Quite encouraging
8 = A lot more or bigger 8 = Very encouraging
9 = A great deal more or
bigger
9 = Extremely encouraging
Health-related Quality of Life Scales
Mental and emotional health: 24 questions with subscales of
anxiety, depression, and loss of behavioural and emotional
control (psychological distress), life satisfaction, general
positive affect and emotional ties (psychological well-being).
General health perceptions: 11 questions with subscales of
sleep disturbance, vitality and general health status.
Compositehealth-relatedqualityoflife: mean of all subscales
of mental and emotional health and all subscales of general
health perceptions.
Compositecognitivefunctionandperformance: 15questions
assessingself-reportedsubscalesofcognitiveacuity,disorienta-
tion and detachment and six questions on self-rated cognitive
performance.
Analogue perceived health: ﬁve questions: patients rated how
they had been feeling during the past month on a scale of
1–10 for each of the following categories: (i) overall or in
general, (ii) physically, (iii) emotionally, (iv) personal life, and
(v) about job or work.
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